Drugs / PCA062
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02375958 | Apr 2015 → Jul 2018 | esophageal cancer, head and neck cancer, triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCA062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02375958 ↗ |
| Route | Intravenous | “administered as a 1-hour intravenous infusion” PMID 35131875 ↗ Apr 2022 |